{"product_id":"breast-cancer-during-pregnancy-how-modern-treatments-can-be-safely-adapted-for-expectant-mothers","title":"Breast Cancer During Pregnancy: How Modern Treatments Can Be Safely Adapted for Expectant Mothers","description":"\u003cp\u003eBreast cancer diagnosed during pregnancy (BCP) is rare but increasingly common, and new research shows that most modern breast cancer treatments can be safely adapted for pregnant patients. An international panel of experts reviewed the latest evidence and concluded that treatment during pregnancy should be the first option, closely mirroring the care given to nonpregnant young women whenever possible. While chemotherapy must be avoided in the first trimester, most other treatments—including surgery, sentinel lymph node biopsy, taxane-based chemotherapy, platinum agents, and dose-dense regimens—can be given safely in the second and third trimesters after careful risk\/benefit assessment. The panel emphasizes that premature delivery should be avoided whenever possible, and that delaying or omitting chemotherapy may actually increase the risk of cancer relapse.\u003c\/p\u003e\n\n\u003ch1\u003eBreast Cancer During Pregnancy: How Modern Treatments Can Be Safely Adapted for Expectant Mothers\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#epidemiology\"\u003eEpidemiology: How Common Is Breast Cancer During Pregnancy?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#prognosis\"\u003ePrognosis: What Does a BCP Diagnosis Mean for Survival?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#diagnosis\"\u003eDiagnosis: How Is BCP Detected and Confirmed?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#imaging\"\u003eImaging Diagnostics: Safe Scans During Pregnancy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pathology\"\u003ePathologic Analysis: Examining the Tumor Tissue\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#brca-testing\"\u003eBRCA Testing: Genetic Considerations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgery\"\u003eLocal Treatment: Surgical Options\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#sentinel-node\"\u003eSentinel Lymph Node Biopsy (SLNB)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#radiation\"\u003eRadiation Therapy: When It Can and Cannot Be Used\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#chemotherapy\"\u003eSystemic Therapy: Chemotherapy During Pregnancy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#anti-her2\"\u003eAnti-HER2 Targeted Therapy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Doctors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eTreat breast cancer during pregnancy as aggressively as outside pregnancy; survival rates are similar when standard treatment is given.\u003c\/li\u003e\n\u003cli\u003eChemotherapy is safe in the second and third trimester; avoid it in the first trimester because malformation risk is about 14%.\u003c\/li\u003e\n\u003cli\u003eDelay or omission of chemotherapy may increase relapse risk; premature delivery should be avoided whenever possible.\u003c\/li\u003e\n\u003cli\u003eSentinel lymph node biopsy with radioactive tracer is safe and accurate during pregnancy; blue dye alone is not recommended.\u003c\/li\u003e\n\u003cli\u003eRadiation therapy and trastuzumab are generally postponed until after delivery due to fetal risks; carboplatin may be considered for triple-negative disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\u003cp\u003eBreast cancer diagnosed during pregnancy (BCP) is a rare and emotionally overwhelming situation, but recent years have brought important news: awareness of treatment options has grown, and more intensive breast cancer treatment is now being offered during pregnancy than ever before. Guidelines for diagnosing and treating BCP were first published in 2006 and updated in 2010, and they carry a clear message: \u003cstrong\u003etreatment during pregnancy should be the first option\u003c\/strong\u003e, not termination of pregnancy or delayed therapy.\u003c\/p\u003e\n\u003cp\u003eAn international group of specialists—including members of the German Cancer Society (DKG) breast cancer guideline consortium, the International Network on Cancer and Infertility in Pregnancy (INCIP) of the European Society of Gynecologic Oncology, and experts in breast cancer and placental research—convened to review the latest scientific literature. Their goal was to answer a specific question: how can recent advances in breast cancer care, including the use of carboplatin, dose-dense chemotherapy, trastuzumab, neoadjuvant therapy, and sentinel lymph node biopsy, be safely adapted for pregnant patients?\u003c\/p\u003e\n\u003cp\u003eThe answer, published in \u003cem\u003eJAMA Oncology\u003c\/em\u003e, is reassuring to many patients: the majority of women diagnosed with breast cancer during pregnancy can and should receive treatment during the pregnancy, with premature delivery avoided whenever possible.\u003c\/p\u003e\n\n\u003ch2 id=\"epidemiology\"\u003eEpidemiology: How Common Is Breast Cancer During Pregnancy?\u003c\/h2\u003e\n\u003cp\u003eBreast cancer is one of the most common malignant tumors diagnosed during pregnancy. Although BCP remains rare overall, its incidence has been \u003cstrong\u003eincreasing steadily over the past few decades\u003c\/strong\u003e. Maternal age has been rising in developed countries since the 1970s—and subsequently in several developing countries—which, combined with the upward trend of breast cancer incidence and the postponement of childbearing, has led to more cases of BCP.\u003c\/p\u003e\n\u003cp\u003eThe numbers are striking: approximately \u003cstrong\u003e1 in 5 breast cancers diagnosed in women aged 25 to 29 years\u003c\/strong\u003e is associated with pregnancy, meaning the cancer is diagnosed either during pregnancy or within the first postpartum year. Population-based studies report that the occurrence of breast cancer diagnosed during pregnancy ranges from \u003cstrong\u003e2.4 to 7.3 per 100,000 pregnancies\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eA Danish study found that \u003cstrong\u003e81% of pregnancies affected by breast cancer were terminated during the first trimester\u003c\/strong\u003e, while other reports found that only \u003cstrong\u003e19% of all BCP cases were diagnosed in the first trimester\u003c\/strong\u003e. Delayed diagnosis is a likely explanation for this discrepancy—many cases are simply not detected until later in the pregnancy or after delivery.\u003c\/p\u003e\n\n\u003ch2 id=\"prognosis\"\u003ePrognosis: What Does a BCP Diagnosis Mean for Survival?\u003c\/h2\u003e\n\u003cp\u003eBreast cancer during pregnancy generally presents at more advanced stages compared to breast cancer in nonpregnant women, and this has historically raised concerns about worse outcomes. However, the evidence tells a more nuanced story.\u003c\/p\u003e\n\u003cp\u003eSeveral earlier studies produced inconsistent results, largely because they included only small numbers of patients. The largest cohort study to date included \u003cstrong\u003e313 patients\u003c\/strong\u003e and, after carefully controlling for cancer stage, prognostic factors, and adjuvant treatment, found that \u003cstrong\u003esurvival was similar for patients with BCP versus nonpregnant patients with breast cancer\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eImportantly, unlike breast cancer diagnosed during the first year after delivery, a diagnosis of breast cancer during pregnancy does \u003cstrong\u003enot\u003c\/strong\u003e appear to be an independent poor prognostic factor—provided that standard treatment is administered. Despite possible pharmacokinetic changes (how the body processes chemotherapy drugs), survival rates did not differ between patients who received chemotherapy during pregnancy versus those who received it after delivery. This means that pregnant patients who receive appropriate, timely treatment can expect outcomes comparable to young nonpregnant patients.\u003c\/p\u003e\n\n\u003ch2 id=\"diagnosis\"\u003eDiagnosis: How Is BCP Detected and Confirmed?\u003c\/h2\u003e\n\u003cp\u003eThe general recommendations for diagnosing BCP have not changed since 2010, but there are important details every pregnant patient should understand. One key principle: \u003cstrong\u003eall palpable breast masses require imaging and imaging-guided biopsy without delay\u003c\/strong\u003e. No woman should be told to \"wait and see\" simply because she is pregnant.\u003c\/p\u003e\n\n\u003ch2 id=\"imaging\"\u003eImaging Diagnostics: Safe Scans During Pregnancy\u003c\/h2\u003e\n\u003cp\u003eBreast ultrasound and mammography can be \u003cstrong\u003esafely and effectively performed during pregnancy\u003c\/strong\u003e. Bilateral mammography (imaging both breasts) is recommended in all women with a confirmed or highly suspicious malignant lesion.\u003c\/p\u003e\n\u003cp\u003eThe radiation dose from a mammogram is less than \u003cstrong\u003e3 mGy\u003c\/strong\u003e (that's 3 milligray, a measurement of absorbed radiation), which corresponds to approximately \u003cstrong\u003e7 weeks of exposure to natural background radiation\u003c\/strong\u003e. The estimated dose to the uterus and fetus is less than \u003cstrong\u003e0.03 μGy\u003c\/strong\u003e—an extremely small amount. For context, the threshold for negative effects of radiation on the fetus is approximately \u003cstrong\u003e100 mGy\u003c\/strong\u003e, with some uncertainty at doses between 50 and 100 mGy. That means a mammogram delivers less than one-three-thousandth of the dose known to cause harm.\u003c\/p\u003e\n\u003cp\u003eDespite these reassuring numbers, many patients and physicians still worry about radiation safety. The authors emphasize that this concern should be discussed openly with the patient. They also note that maternal and fetal radiation exposure depends on gestational age, the anatomic site being imaged, the imaging modality, and technique.\u003c\/p\u003e\n\u003cp\u003eContrast-enhanced magnetic resonance imaging (MRI) is \u003cstrong\u003enot recommended\u003c\/strong\u003e during pregnancy because the use of iodinated and gadolinium-based contrast agents has not been sufficiently studied in pregnant women. Similarly, whole-body MRI has not been studied enough in breast cancer in general, and although pharmacologic agents used for diagnostic nuclear medicine and positron-emission tomography (PET) probably do not result in radiation exposure exceeding 50 mGy, their use is \u003cstrong\u003enot recommended during pregnancy\u003c\/strong\u003e. Imaging and staging procedures should only be performed in advanced stages in which they might alter treatment decisions.\u003c\/p\u003e\n\n\u003ch2 id=\"pathology\"\u003ePathologic Analysis: Examining the Tumor Tissue\u003c\/h2\u003e\n\u003cp\u003eThe gold standard for diagnosing BCP is a \u003cstrong\u003ecore biopsy\u003c\/strong\u003e (removing a small sample of tissue with a needle) of the suspicious lesion. The pathologist who examines the tissue must be informed about the pregnancy, as this can affect interpretation.\u003c\/p\u003e\n\u003cp\u003eOverall, the histological features of BCP tumors do not differ from those in young nonpregnant women with breast cancer. Almost all BCP tumors are \u003cstrong\u003eductal invasive\u003c\/strong\u003e (starting in the milk ducts and spreading outward), mainly \u003cstrong\u003ehormone receptor–negative\u003c\/strong\u003e and \u003cstrong\u003eundifferentiated\u003c\/strong\u003e (meaning the cancer cells look very abnormal and grow aggressively).\u003c\/p\u003e\n\u003cp\u003eIn general, tumor mutations do not differ between pregnant and nonpregnant young women, although small studies have shown significant differences in gene expression analyses. The authors caution that no definite conclusions for everyday clinical practice can be drawn from these analyses yet. A major challenge for future research is choosing the right control group—matching cohorts by treatment, histologic subtype, and age is essential.\u003c\/p\u003e\n\n\u003ch2 id=\"brca-testing\"\u003eBRCA Testing: Genetic Considerations\u003c\/h2\u003e\n\u003cp\u003eTaking a family history is a prerequisite for any breast cancer patient, and genetic counseling should be offered according to national guidelines, which differ substantially between countries. \u003cstrong\u003eBRCA testing is becoming treatment-relevant\u003c\/strong\u003e, especially because the majority of BCP cases are triple-negative breast cancer (TNBC)—a subtype that lacks estrogen receptors, progesterone receptors, and HER2 amplification.\u003c\/p\u003e\n\u003cp\u003eHere is a number that matters for young patients: in young patients with TNBC, the probability of detecting a \u003cstrong\u003egermline BRCA mutation is approximately 20%\u003c\/strong\u003e. This means that one in five young women with this breast cancer subtype carries an inherited genetic mutation that could have implications not only for her own treatment but also for future family planning and relatives' cancer risk.\u003c\/p\u003e\n\n\u003ch2 id=\"surgery\"\u003eLocal Treatment: Surgical Options\u003c\/h2\u003e\n\u003cp\u003eIn general, the surgical approach for pregnant patients is the same as for nonpregnant patients. \u003cstrong\u003eMastectomy is not recommended solely on the basis of pregnancy\u003c\/strong\u003e or because of a possible consequent delay of radiation therapy (RT). Breast-conserving surgery (removing only the tumor and a margin of surrounding tissue) is a valid option when appropriate.\u003c\/p\u003e\n\u003cp\u003eImmediate breast reconstruction after mastectomy is an essential component of treatment for breast cancer patients, particularly for young women. Based on a single published experience, \u003cstrong\u003etissue expander insertion appears to ensure a short operation time\u003c\/strong\u003e and does not seem to be associated with considerable harm to the mother or the fetus. Therefore, this surgical technique could be considered in the multidisciplinary treatment of women diagnosed with breast cancer during pregnancy.\u003c\/p\u003e\n\u003cp\u003eHowever, more complex reconstruction, such as flap reconstruction (using tissue from other parts of the body), is \u003cstrong\u003enot a standard option during pregnancy\u003c\/strong\u003e. One important practical reason: breast size differs between pregnant and nonpregnant states, so reconstruction performed during pregnancy may not produce optimal long-term cosmetic results.\u003c\/p\u003e\n\n\u003ch2 id=\"sentinel-node\"\u003eSentinel Lymph Node Biopsy (SLNB)\u003c\/h2\u003e\n\u003cp\u003eThe sentinel lymph node is the first lymph node to which cancer cells are likely to spread. Checking this node helps doctors determine whether the cancer has spread, without removing all the lymph nodes in the armpit. Recommendations from the American Society of Clinical Oncology (ASCO) historically stated that pregnant patients should \u003cstrong\u003enot\u003c\/strong\u003e undergo SLNB, based on older cohort studies and informal consensus. But the evidence has evolved.\u003c\/p\u003e\n\u003cp\u003eStudies now show that SLNB can be \u003cstrong\u003esafely performed during pregnancy\u003c\/strong\u003e. The procedure uses small amounts of injected radioactive material that stays mostly at the injection site, which is shortly afterward removed surgically. The radiation doses absorbed by the fetus are mostly \u003cstrong\u003eless than 20 μGy\u003c\/strong\u003e for 10 to 20 MBq (megabecquerels, the unit of radioactivity)—roughly 1 μGy per MBq, as measured in experimental studies and Medical Internal Radiation Dose Committee models.\u003c\/p\u003e\n\u003cp\u003eFrom a maternal oncologic point of view, SLNB appears to be accurate and safe, with only \u003cstrong\u003e1 unsuccessful mapping and 1 recurrence among 97 patients with BCP\u003c\/strong\u003e. Pregnant patients should be offered SLNB rather than full axillary lymph node clearance whenever it is indicated according to general practice for nonpregnant patients.\u003c\/p\u003e\n\u003cp\u003ePractical recommendations for pregnant patients receiving SLNB:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eInject the radioactive colloid in the morning (a 1-day protocol) to minimize radiation exposure to the fetus.\u003c\/li\u003e\n  \u003cli\u003eUse the \u003cstrong\u003eradioactive tracer\u003c\/strong\u003e as the preferred method.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBlue dye alone is not recommended\u003c\/strong\u003e—it carries a low (approximately 1%) but potentially harmful risk of a severe allergic (anaphylactic) reaction in the mother.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn one small series of 25 women who underwent SLNB during pregnancy, 7 received blue dye for mapping. The authors note that blue dye is not recommended even outside pregnancy as a sole procedure, so avoiding it in pregnant patients is consistent with best practice.\u003c\/p\u003e\n\n\u003ch2 id=\"radiation\"\u003eRadiation Therapy: When It Can and Cannot Be Used\u003c\/h2\u003e\n\u003cp\u003eRadiation therapy during pregnancy is \u003cstrong\u003erarely indicated\u003c\/strong\u003e for BCP. In general, the recommendation is to postpone RT until after delivery. The available information on long-term consequences of radiation exposure in the womb is limited, and two factors must be weighed: the dose to the fetus and the risk that radiation exposure causes adverse effects.\u003c\/p\u003e\n\u003cp\u003eUnderstanding radiation risk requires distinguishing between two types of effects:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDeterministic (teratogenic) effects\u003c\/strong\u003e: These are dose-dependent and occur only above a certain threshold. They include miscarriage, birth defects, and neurodevelopmental problems.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStochastic (carcinogenic) effects\u003c\/strong\u003e: The severity of these effects is independent of dose, but the probability is dose-dependent and has no threshold. The main stochastic effect is the induction of childhood cancer and leukemia.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf radiation occurs in very early pregnancy (often before the pregnancy is diagnosed), it generally leads to spontaneous abortion. From the third week of pregnancy onward, malformations can occur. Radiation exposure may also affect the developing central nervous system, potentially causing neuropsychological and behavioral dysfunction.\u003c\/p\u003e\n\u003cp\u003eThe reassuring data point: at low doses, the incidence of childhood cancer and leukemia (naturally \u003cstrong\u003e0.2% to 0.3% for ages 0 to 15 years\u003c\/strong\u003e) does not appear to be increased. Following a dose of \u003cstrong\u003e10 mGy\u003c\/strong\u003e, the relative risk rises to \u003cstrong\u003e1.4\u003c\/strong\u003e—still a very low absolute risk. Radiation's effect on germline mutations in eggs (oocytes) has not been shown to cause negative effects in humans.\u003c\/p\u003e\n\u003cp\u003eThe radiation dose received by the fetus depends on the distance between the radiation field and the position of the fetus (which changes with gestational age), the amount of radiation leakage outside the field, and the use of effective shielding, which can reduce the dose by \u003cstrong\u003e50% to 75%\u003c\/strong\u003e. During the first months of pregnancy, the uterus does not extend outside the true pelvis, and with appropriate techniques and shielding, the dose to the fetus will be only \u003cstrong\u003e0.1% to 0.3% of the prescribed dose to the breast\u003c\/strong\u003e—resulting in a very low risk of inducing malformations.\u003c\/p\u003e\n\u003cp\u003eSeveral case reports describe radiation therapy administered for BCP with low fetal doses and healthy babies delivered. Therefore, RT \u003cstrong\u003emight be considered in the first or early second trimester\u003c\/strong\u003e if the risk of delaying or omitting RT is believed to outweigh the risk of harming the fetus. In practice, this is a deeply individualized decision that should be made by the entire care team with the patient.\u003c\/p\u003e\n\n\u003ch2 id=\"chemotherapy\"\u003eSystemic Therapy: Chemotherapy During Pregnancy\u003c\/h2\u003e\n\u003cp\u003eThis is the most detailed and clinically important section of the review. The overarching principle: \u003cstrong\u003etreat pregnant patients with BCP during the second and third trimester, following guidelines for nonpregnant young patients as closely as possible\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFirst trimester warning.\u003c\/strong\u003e Chemotherapy is \u003cstrong\u003econtraindicated during the first trimester\u003c\/strong\u003e because of a higher risk of inducing fetal malformations. The US National Toxicology Program monograph reports a prevalence of malformations of \u003cstrong\u003e14% if chemotherapy is given in the first trimester\u003c\/strong\u003e, declining to \u003cstrong\u003e3% if chemotherapy is applied later in pregnancy\u003c\/strong\u003e. For comparison, the reported rate of major malformations in the general population is approximately \u003cstrong\u003e3% in the United States and 6.7% in a German registry\u003c\/strong\u003e. This means that chemotherapy in the second and third trimester carries no higher risk of major birth defects than the background rate in the general population.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhy not wait until after delivery?\u003c\/strong\u003e Postponing chemotherapy until after delivery might seem like a safe option, but data in nonpregnant young women indicate that \u003cstrong\u003edelaying or postponing chemotherapy might increase the risk of relapse\u003c\/strong\u003e. This is why the recommendation is to treat during pregnancy rather than wait.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhich drugs are safe and recommended?\u003c\/strong\u003e The standard adjuvant (post-surgery) or neoadjuvant (pre-surgery) combination recommended for nonpregnant patients includes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnthracyclines\u003c\/strong\u003e (epirubicin or doxorubicin)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eCyclophosphamide\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTaxanes\u003c\/strong\u003e (paclitaxel or docetaxel)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOne of the most widely used regimens—also used during pregnancy—is \u003cstrong\u003eepirubicin hydrochloride plus cyclophosphamide, followed by weekly paclitaxel\u003c\/strong\u003e. The reverse sequence (starting with a taxane) is also possible; the decision may be based on gestational age and other clinical factors.\u003c\/p\u003e\n\u003cp\u003eFluorouracil is \u003cstrong\u003eno longer indicated\u003c\/strong\u003e for breast cancer therapy because it does not add any benefit to an anthracycline-taxane–based regimen.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePlatinum agents (carboplatin).\u003c\/strong\u003e Platinum derivatives may play a role in treating patients with triple-negative breast cancer. Neoadjuvant trials demonstrated \u003cstrong\u003esignificantly higher pathological complete response rates\u003c\/strong\u003e (meaning no cancer cells remain in the removed tissue) when carboplatin was added, although survival data are still immature. Carboplatin therapy \u003cstrong\u003emay be considered during the second and third trimesters\u003c\/strong\u003e of pregnancy. It remains unclear which platinum drug is most effective, but carboplatin may have less overall toxicity than cisplatin.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDose-dense regimens.\u003c\/strong\u003e Dose-dense chemotherapy (the same dose given over a shorter interval, such as every 2 weeks instead of every 3 weeks) leads to better survival than conventionally dosed regimens, especially in high-risk patients. \u003cstrong\u003eDose-dense chemotherapy appears to be an acceptable option during pregnancy\u003c\/strong\u003e. However, \u003cstrong\u003eintensified dose-dense (IDD) chemotherapy\u003c\/strong\u003e—a higher dose over a shorter interval—has not been studied systematically in pregnancy. The high rate of grade 2 to 4 anemia (\u003cstrong\u003e59%\u003c\/strong\u003e), with need for transfusion in \u003cstrong\u003e28%\u003c\/strong\u003e of patients, and the high risk of febrile neutropenia (\u003cstrong\u003e7% despite primary G-CSF prophylaxis\u003c\/strong\u003e) mandate a strict risk\/benefit analysis. \u003cstrong\u003eIDD cannot generally be recommended in BCP.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eHow Chemotherapy Is Dosed in Pregnancy\u003c\/h3\u003e\n\u003cp\u003ePregnancy causes significant physiological changes that affect how drugs move through the body. An increased activity of major enzymes involved in the metabolism of taxanes and anthracyclines—including cytochrome P450 isoforms such as CYP3A4 and CYP2C8—has been observed in the late trimesters of pregnancy, potentially resulting in decreased drug exposure. Because albumin concentrations (blood proteins that bind to drugs) also vary significantly during pregnancy, and taxanes are highly protein-bound, this can lead to significant changes in taxane pharmacokinetics.\u003c\/p\u003e\n\u003cp\u003ePharmacokinetic data comparing anthracyclines and taxanes in pregnant versus nonpregnant patients showed that \u003cstrong\u003etaxane serum levels were significantly decreased during pregnancy, especially for paclitaxel\u003c\/strong\u003e. Conversely, exposure to anthracyclines was \u003cstrong\u003enot significantly modified by pregnancy\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eSo should doses be increased? The authors say \u003cstrong\u003eno\u003c\/strong\u003e, for several important reasons:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eIncreasing doses could result in severe toxic effects, with potential harm for mother and newborn.\u003c\/li\u003e\n  \u003cli\u003eIn overweight women, who also have altered pharmacokinetics, the dose is not increased either.\u003c\/li\u003e\n  \u003cli\u003eChemotherapy appears to be as active during pregnancy as outside of it, despite lower blood levels.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eStandard practice is to \u003cstrong\u003edose according to actual body weight\u003c\/strong\u003e and avoid underdosing. On the basis of 11 reported cases without outcome data, increasing the dose cannot be recommended.\u003c\/p\u003e\n\u003cp\u003eData on transplacental transfer (how much drug crosses from mother to baby) are reassuring for both anthracyclines and taxanes, though there is marked variability between patients, particularly with docetaxel. For fetal safety, \u003cstrong\u003epaclitaxel should probably be preferred over docetaxel\u003c\/strong\u003e in pregnant patients. Significant transplacental transfer of carboplatin has been demonstrated, and long-term data from the children exposed in the womb remain limited.\u003c\/p\u003e\n\u003cp\u003eOne finding that deserves attention: a \u003cstrong\u003esignificantly higher incidence of small-for-gestational-age neonates\u003c\/strong\u003e is observed when chemotherapy is given during pregnancy. This suggests chemotherapy may have a toxic influence on placental development, leading to placental malfunction—for example, through incomplete trophoblast invasion into the uterus, resulting in decreased transfer of nutrients to the fetus. Organogenesis (the formation of organs) is complete at approximately the \u003cstrong\u003e10th week of gestation\u003c\/strong\u003e, which is why chemotherapy can be considered from that point onward. However, trophoblast invasion of the placenta is not completed until approximately \u003cstrong\u003eweek 20\u003c\/strong\u003e—so starting chemotherapy at week 14 might interfere with the later stages of placental development.\u003c\/p\u003e\n\n\u003ch3\u003eGeneral Rules for Safe Chemotherapy During Pregnancy\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMaintain dose intensity.\u003c\/strong\u003e Timing of chemotherapy start in relation to delivery needs careful planning.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUse published standard protocols.\u003c\/strong\u003e Neither decrease nor increase the dose, and do not increase treatment intervals.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDose according to actual body weight.\u003c\/strong\u003e This is crucial to avoid underdosing, which is a risk factor during pregnancy due to physiologic variation in drug processing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not increase the dose.\u003c\/strong\u003e Some data show a lower area under the concentration-time curve and lower maximum serum concentration in women treated with taxanes during pregnancy, but dose escalation cannot be recommended based on current evidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscontinue chemotherapy at approximately week 35 to 37 of gestation.\u003c\/strong\u003e This allows the bone marrow to recover and prevents hematologic toxicity (low blood counts) in both mother and child at the time of delivery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"anti-her2\"\u003eAnti-HER2 Targeted Therapy\u003c\/h2\u003e\n\u003cp\u003eTrastuzumab (Herceptin) is an integral part of primary treatment for women with HER2-positive breast cancer. In nonpregnant patients, starting trastuzumab as early as possible—and combining it with chemotherapy rather than giving it sequentially—is associated with better long-term outcomes.\u003c\/p\u003e\n\u003cp\u003eHowever, \u003cstrong\u003etrastuzumab is generally not recommended during pregnancy\u003c\/strong\u003e due to its potential fetal toxicity. In a recent review, the authors identified 18 reports in the literature of using trastuzumab during pregnancy. The key concerns are \u003cstrong\u003efetal toxicity and a condition called oligohydramnios\u003c\/strong\u003e (low amniotic fluid) or \u003cstrong\u003eanhydramnios\u003c\/strong\u003e (absence of amniotic fluid), which can severely affect fetal development.\u003c\/p\u003e\n\u003cp\u003eA careful risk\/benefit analysis needs to be discussed with the patient, since the early start of trastuzumab improves survival but may harm the fetus. There are \u003cstrong\u003eno data for pertuzumab\u003c\/strong\u003e (another HER2-targeted drug) during pregnancy, so its use is not recommended. Endocrine treatments (such as tamoxifen or aromatase inhibitors) are also \u003cstrong\u003enot indicated during pregnancy\u003c\/strong\u003e. For women who require these agents, treatment is typically deferred until after delivery.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eThe central message of this review is hopeful: a breast cancer diagnosis during pregnancy is no longer a reason to terminate the pregnancy or to delay all cancer treatment. The international expert panel's updated recommendations can be summarized as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreat the cancer as aggressively during pregnancy as you would outside of pregnancy.\u003c\/strong\u003e The survival rates are similar when standard treatment is given.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAvoid premature delivery.\u003c\/strong\u003e Delivering a baby early to start cancer treatment is usually not necessary and may harm the baby. Chemotherapy can safely continue until approximately weeks 35 to 37.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSecond and third trimester chemotherapy is safe for the baby\u003c\/strong\u003e, with no higher risk of major birth defects than the general population (3% with second\/third trimester chemo vs. 14% in the first trimester and 3%–6.7% in the general population).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStandard drug regimens work.\u003c\/strong\u003e Epirubicin-cyclophosphamide followed by weekly paclitaxel is the preferred regimen. Carboplatin can be added for triple-negative disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgery is safe.\u003c\/strong\u003e Breast-conserving surgery or mastectomy is offered on the same indications as in nonpregnant women. Sentinel node biopsy with radioactive tracer is safe for both mother and fetus.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadiation and trastuzumab are generally postponed until after delivery\u003c\/strong\u003e, with rare exceptions in early pregnancy where the benefits may outweigh the risks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/h2\u003e\n\u003cp\u003eThis is a narrative review, not a randomized controlled trial. The authors note several important limitations:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eData on BCP come largely from small cohort studies and case reports, which limits the strength of the evidence.\u003c\/li\u003e\n  \u003cli\u003ePharmacokinetic data in pregnancy are limited; the observation that taxane levels are lower in pregnant women is based on small numbers, and no outcome data support increasing the dose.\u003c\/li\u003e\n  \u003cli\u003eLong-term outcomes for children exposed to chemotherapy in the womb are not yet fully known. One study found a higher rate of small-for-gestational-age babies, indicating a possible effect on placental function that needs further investigation.\u003c\/li\u003e\n  \u003cli\u003eThere are \u003cstrong\u003eno data on pertuzumab\u003c\/strong\u003e or nab-paclitaxel during pregnancy, so these agents cannot be recommended.\u003c\/li\u003e\n  \u003cli\u003eWhole-body MRI has not been sufficiently studied in breast cancer in general, and its use in pregnancy is not established.\u003c\/li\u003e\n  \u003cli\u003eGene expression differences between BCP and nonpregnant tumors have been seen in small series, but no definite conclusions for clinical practice can be drawn yet. Choosing an appropriate control cohort remains a challenge for future research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Doctors\u003c\/h2\u003e\n\u003cp\u003eThe authors call for a multidisciplinary approach involving breast cancer specialists, maternal-fetal medicine experts, pathologists, and neonatologists. They also urge systematic data collection whenever possible, so that each case can contribute to the growing body of knowledge about BCP.\u003c\/p\u003e\n\u003cp\u003eFor patients facing this diagnosis, the practical takeaways are:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGet a biopsy without delay.\u003c\/strong\u003e Ultrasound and mammography are safe during pregnancy; do not postpone evaluation of a breast lump.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about sentinel node biopsy.\u003c\/strong\u003e It is safe and accurate in pregnancy when performed with a radioactive tracer using the 1-day protocol.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss timing of chemotherapy.\u003c\/strong\u003e If you are in the first trimester, chemotherapy will likely be delayed until week 10–14. If you are in the second or third trimester, treatment can begin promptly.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlan delivery around chemotherapy.\u003c\/strong\u003e Chemotherapy is typically stopped at weeks 35 to 37 to allow blood counts to recover before delivery. Avoid premature induction unless medically necessary.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials and registries.\u003c\/strong\u003e Your care team can help you understand whether your treatment plan can be contributed to research efforts that help future patients.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eEvery case is unique, and the final treatment plan should be tailored to the individual patient's cancer biology, gestational age, and personal values. But the overarching principle from this expert panel is clear: \u003cstrong\u003epregnancy should not be a barrier to receiving optimal breast cancer care\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eCan I receive breast cancer treatment while I am pregnant?\u003c\/h3\u003e\n\u003cp\u003eYes. Experts now recommend treating breast cancer during pregnancy rather than delaying treatment or terminating the pregnancy. Surgery, sentinel lymph node biopsy, and certain chemotherapy regimens can be safely given in the second and third trimesters. Chemotherapy is avoided in the first trimester. Your care team will tailor treatment to your cancer and gestational age.\u003c\/p\u003e\n\u003ch3\u003eIs chemotherapy safe for my baby during pregnancy?\u003c\/h3\u003e\n\u003cp\u003eChemotherapy given in the second and third trimester does not raise the risk of major birth defects above the general population rate of about 3%. In the first trimester, however, the risk is about 14%. Doctors stop chemotherapy around weeks 35 to 37 so your blood counts recover before delivery. The doctor will discuss risks and benefits with you.\u003c\/p\u003e\n\u003ch3\u003eWhy is chemotherapy not delayed until after my baby is born?\u003c\/h3\u003e\n\u003cp\u003eDelaying or postponing chemotherapy may increase the risk of breast cancer relapse. Data from nonpregnant young women show that waiting can be harmful. Treating during pregnancy, when possible, gives outcomes similar to those of nonpregnant patients. Your oncologist will plan the safest timing for you and your baby.\u003c\/p\u003e\n\u003ch3\u003eCan I have surgery for breast cancer while pregnant?\u003c\/h3\u003e\n\u003cp\u003eYes. Mastectomy or breast-conserving surgery is offered on the same indications as for nonpregnant women. Pregnancy alone is not a reason to choose mastectomy. Sentinel lymph node biopsy with a radioactive tracer can be performed safely and accurately during pregnancy. Blue dye alone is not recommended due to allergy risk.\u003c\/p\u003e\n\u003ch3\u003eIs radiation therapy safe during pregnancy?\u003c\/h3\u003e\n\u003cp\u003eRadiation therapy is usually postponed until after delivery. It may be considered in the first or early second trimester in rare cases if the benefit is believed to outweigh the risk. The fetal dose can be reduced by shielding, but long-term effects are not well studied. This decision is made individually by your care team.\u003c\/p\u003e\n\u003ch3\u003eWhat is the survival outlook for breast cancer diagnosed during pregnancy?\u003c\/h3\u003e\n\u003cp\u003eWhen standard treatment is given, survival is similar to that of nonpregnant young women with breast cancer. The largest cohort study, with 313 patients, found no difference in survival after accounting for cancer stage and treatment. A diagnosis during pregnancy is not an independent poor prognostic factor if you receive appropriate, timely treatment.\u003c\/p\u003e\n\u003ch3\u003eHow is breast cancer diagnosed during pregnancy without harming the baby?\u003c\/h3\u003e\n\u003cp\u003eBreast ultrasound and mammography are safe during pregnancy. The fetal radiation dose from a mammogram is extremely low, less than 0.03 μGy, far below the 100 mGy threshold for harm. A core biopsy is the gold standard. Do not delay evaluation of a breast lump; all palpable masses require imaging and biopsy without delay.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Breast Cancer Diagnosed During Pregnancy Adapting Recent Advances in Breast Cancer Care for Pregnant Patients\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Sibylle Loibl, MD, PhD; André Schmidt, PhD; Oreste Gentilini, MD; Bella Kaufman, MD; Christine Kuhl, MD; Carsten Denkert, MD; Gunter von Minckwitz, MD; Anastasia Parokonnaya, MD; Hanne Stensheim, MD, PhD; Christoph Thomssen, MD; Kristel Van Calsteren, MD, PhD; Philip Poortmans, MD, PhD; Paul Berveiller, MD; Udo R. Markert, MD; Frederic Amant, MD, PhD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e \u003cem\u003eJAMA Oncology\u003c\/em\u003e, November 2015, Volume 1, Number 8, pages 1145–1153. doi:10.1001\/jamaoncol.2015.2413. Published online August 6, 2015; corrected November 12, 2015.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research published in a leading medical journal. It is intended for educational purposes and does not replace individualized medical advice from your oncology and obstetrics care teams.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47400024768668,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.fr\/products\/breast-cancer-during-pregnancy-how-modern-treatments-can-be-safely-adapted-for-expectant-mothers","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}